Open access
Open access
Powered by Google Translator Translator

Covid-19

Observational study finds the effectiveness of mRNA vaccination against Covid-19 hospitalization was lower (77%) among immunocompromised adults than among immunocompetent adults (90%).

18 Nov, 2021 | 08:52h | UTC

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021 – CDC Morbidity and Mortality Weekly Report

Related:

CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.

 

Commentary on Twitter (thread – click for more)

 

8 lingering questions about the new Covid pills from Merck and Pfizer.

18 Nov, 2021 | 08:46h | UTC

8 lingering questions about the new Covid pills from Merck and Pfizer – STAT

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Case-control study: sleep disorders linked to more severe outcomes from COVID-19, study suggests.

17 Nov, 2021 | 08:50h | UTC

News Release: Sleep disorders linked with more severe outcomes from COVID-19, study suggests – Cleveland Clinic

Original Study: Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System – JAMA Network Open

Commentary: Some sleep disorders may lead to worse COVID-19 outcomes – CIDRAP

 

Commentary on Twitter

 

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic.

17 Nov, 2021 | 08:56h | UTC

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic – European Heart Journal

Part 1—epidemiology, pathophysiology, and diagnosis

Part 2—care pathways, treatment, and follow-up

News release: European Society of Cardiology COVID-19 guidance launched – European Society of Cardiology

 

Commentaries on Twitter

 

Observational study found monitoring outpatients with Covid-19 using text messages that allowed the report of worsening symptoms was associated with improved outcomes.

17 Nov, 2021 | 08:53h | UTC

Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home – Annals of Internal Medicine

News Release: Automated Texting System Saved Lives Weekly During First COVID Surge – Penn Medicine

Commentaries:

Monitoring outpatients by text appeared to reduce mortality from COVID-19 – ACP Internist

Texting saved lives during Covid. What does that mean for health care’s future? – STAT

 

Commentary from the author on Twitter (thread – click for more)

 

The big questions about Covid-19 booster shots – “From the why to the who, we still need a lot of answers about booster shots”.

17 Nov, 2021 | 08:48h | UTC

The big questions about Covid-19 booster shots – Vox

 

Commentary on Twitter

 

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries.

17 Nov, 2021 | 08:40h | UTC

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries – HealthDay

See also:

Pfizer agrees to license generic versions of its COVID-19 pill — in some countries – NPR

Pfizer and Medicines Patent Pool Reach ‘Ground-breaking’ Voluntary Licensing Deal for New COVID-19 Treatment Pill – Health Policy Watch

Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countries – The New York Times (a few articles per month are free)

 

MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – “The deal, however, only covers 53 percent of the world’s population and excludes people in several upper-middle-income countries, leaving this promising medicine out of reach for millions”.

17 Nov, 2021 | 08:38h | UTC

MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – Médecins Sans Frontières

 

Commentary on Twitter

 

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

17 Nov, 2021 | 08:42h | UTC

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians – The Journal of the American Board of Family Medicine

Related:

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome.

16 Nov, 2021 | 08:48h | UTC

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

IDSA/ASM Consensus Review Document: Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping.

16 Nov, 2021 | 08:50h | UTC

Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: An IDSA/ASM Consensus Review Document – Clinical Infectious Diseases

News Release: New review article outlines potential of SARS-CoV-2 genetic sequencing in patient care – American Society for Microbiology

 

Review: Vaccine-induced immune thrombotic thrombocytopenia.

16 Nov, 2021 | 08:46h | UTC

Vaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology

Related:

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

 

Covid: Austria introduces lockdown for unvaccinated.

16 Nov, 2021 | 08:43h | UTC

Covid: Austria introduces lockdown for unvaccinated – BBC

See also: Austria orders nationwide lockdown for the unvaccinated – Associated Press

 

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding.

16 Nov, 2021 | 08:42h | UTC

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding – The BMJ

 

Commentary on Twitter

 

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more.

16 Nov, 2021 | 08:41h | UTC

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used.

16 Nov, 2021 | 08:39h | UTC

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

[Preprint] Risk of severe COVID-19 is rare among fully vaccinated individuals in England.

14 Nov, 2021 | 20:10h | UTC

Commentary: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical

Original Study: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv

 

Phase 4 RCT: Concomitant administration of COVID-19 vaccines (AstraZeneca or Pfizer) with seasonal influenza vaccines in adults is safe and preserves antibody responses to both vaccines.

14 Nov, 2021 | 20:14h | UTC

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

 

Large populational study finds prior SARS-CoV-2 infection reduces the risk of breakthrough infection following mRNA vaccination.

14 Nov, 2021 | 20:12h | UTC

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Commentaries:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Commentary on Twitter

 

Populational study in Qatar showed the effectiveness against SARS-CoV-2 Delta-induced severe, critical or fatal disease was 93.4% for the Pfizer vaccine and 96.1% for Moderna.

14 Nov, 2021 | 20:11h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Commentary on Twitter

 

What influences people’s responses to public health messages for managing risks and preventing infectious diseases? A rapid systematic review of the evidence and recommendations.

14 Nov, 2021 | 20:06h | UTC

What influences people’s responses to public health messages for managing risks and preventing infectious diseases? A rapid systematic review of the evidence and recommendations – BMJ Open

 

Commentary on Twitter

 

SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study.

14 Nov, 2021 | 20:05h | UTC

News Release: SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study – Harvard Medical School

Original study: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study – Journal of Clinical Oncology

 

Commentary from the author on Twitter (thread – click for more)

 

Editorial: COVID is disrupting scientific careers around the world.

14 Nov, 2021 | 20:08h | UTC

COVID is disrupting scientific careers around the world – Nature

See also:

Scientists count the career costs of COVID – Nature

Potentially long-lasting effects of the pandemic on scientists – Nature

 

RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults.

12 Nov, 2021 | 10:43h | UTC

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet

Invited Commentary: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet

Related: WHO issues emergency use approval for India’s Covaxin.

 

Commentary on Twitter

 

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

12 Nov, 2021 | 10:39h | UTC

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – Nature

Related:

[Preprint] Study confirms children’s extremely low risk of death from Covid-19 – “99·995% of children and young people with a positive SARS-CoV-2 test survived”.

Study: Children and young people remain at low risk of COVID-19 mortality

 

Commentaries on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.